RZ402 is an orally available plasma kallikrein inhibitor in development for the treatment of diabetic macular edema RZ402 is an orally available plasma kallikrein inhibitor in development for the treatment of diabetic macular edema

Read the original:
FDA Clears Rezolute’s IND Application for RZ402

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh